The FDA recently approved the radiopharmaceutical lutetium Lu 177 dotatate to treat patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors. The approval was based on results of the phase III NETTER-1 trial.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2pXKPdS
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου